Literature DB >> 26442696

Microglial malfunction: the third rail in the development of Alzheimer's disease.

Siddhita D Mhatre1, Connie A Tsai2, Amanda J Rubin2, Michelle L James3, Katrin I Andreasson4.   

Abstract

Studies of Alzheimer's disease (AD) have predominantly focused on two major pathologies: amyloid-β (Aβ) and hyperphosphorylated tau. These misfolded proteins can accumulate asymptomatically in distinct regions over decades. However, significant Aβ accumulation can be seen in individuals who do not develop dementia, and tau pathology limited to the transentorhinal cortex, which can appear early in adulthood, is usually clinically silent. Thus, an interaction between these pathologies appears to be necessary to initiate and propel disease forward to widespread circuits. Recent multidisciplinary findings strongly suggest that the third factor required for disease progression is an aberrant microglial immune response. This response may initially be beneficial; however, a maladaptive microglial response eventually develops, fueling a feed-forward spread of tau and Aβ pathology.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Aβ peptide; Braak stages; GWAS; epigenomics; microglia; tau phosphorylation; transcriptomics

Mesh:

Year:  2015        PMID: 26442696      PMCID: PMC4670239          DOI: 10.1016/j.tins.2015.08.006

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  134 in total

1.  Genetic susceptibility for Alzheimer disease neuritic plaque pathology.

Authors:  Joshua M Shulman; Kewei Chen; Brendan T Keenan; Lori B Chibnik; Adam Fleisher; Pradeep Thiyyagura; Auttawut Roontiva; Cristin McCabe; Nikolaos A Patsopoulos; Jason J Corneveaux; Lei Yu; Matthew J Huentelman; Denis A Evans; Julie A Schneider; Eric M Reiman; Philip L De Jager; David A Bennett
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

2.  Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease.

Authors:  Minerva M Carrasquillo; Julia E Crook; Otto Pedraza; Colleen S Thomas; V Shane Pankratz; Mariet Allen; Thuy Nguyen; Kimberly G Malphrus; Li Ma; Gina D Bisceglio; Rosebud O Roberts; John A Lucas; Glenn E Smith; Robert J Ivnik; Mary M Machulda; Neill R Graff-Radford; Ronald C Petersen; Steven G Younkin; Nilüfer Ertekin-Taner
Journal:  Neurobiol Aging       Date:  2014-08-04       Impact factor: 4.673

3.  Plasma clusterin and the risk of Alzheimer disease.

Authors:  Elisabeth M C Schrijvers; Peter J Koudstaal; Albert Hofman; Monique M B Breteler
Journal:  JAMA       Date:  2011-04-06       Impact factor: 56.272

4.  Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia.

Authors:  Xianwu Li; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  FASEB J       Date:  2015-01-15       Impact factor: 5.191

5.  MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.

Authors:  Michael Koslowski; Ugur Sahin; Karl Dhaene; Christoph Huber; Ozlem Türeci
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor.

Authors:  Christopher N Parkhurst; Guang Yang; Ipe Ninan; Jeffrey N Savas; John R Yates; Juan J Lafaille; Barbara L Hempstead; Dan R Littman; Wen-Biao Gan
Journal:  Cell       Date:  2013-12-19       Impact factor: 41.582

7.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

Review 8.  Noninvasive molecular imaging of neuroinflammation.

Authors:  Andreas H Jacobs; Bertrand Tavitian
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-02       Impact factor: 6.200

9.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

10.  Alzheimer's loci: epigenetic associations and interaction with genetic factors.

Authors:  Lori B Chibnik; Lei Yu; Matthew L Eaton; Gyan Srivastava; Julie A Schneider; Manolis Kellis; David A Bennett; Philip L De Jager
Journal:  Ann Clin Transl Neurol       Date:  2015-04-24       Impact factor: 4.511

View more
  51 in total

1.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

Review 2.  Microglial priming in Alzheimer's disease.

Authors:  Jun-Wei Li; Yu Zong; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

Review 3.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

4.  Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases.

Authors:  Mariet Allen; Xue Wang; Jeremy D Burgess; Jens Watzlawik; Daniel J Serie; Curtis S Younkin; Thuy Nguyen; Kimberly G Malphrus; Sarah Lincoln; Minerva M Carrasquillo; Charlotte Ho; Paramita Chakrabarty; Samantha Strickland; Melissa E Murray; Vivek Swarup; Daniel H Geschwind; Nicholas T Seyfried; Eric B Dammer; James J Lah; Allan I Levey; Todd E Golde; Cory Funk; Hongdong Li; Nathan D Price; Ronald C Petersen; Neill R Graff-Radford; Steven G Younkin; Dennis W Dickson; Julia R Crook; Yan W Asmann; Nilüfer Ertekin-Taner
Journal:  Alzheimers Dement       Date:  2017-10-31       Impact factor: 21.566

Review 5.  Developmental roles of microglia: A window into mechanisms of disease.

Authors:  Sarah R Anderson; Monica L Vetter
Journal:  Dev Dyn       Date:  2018-12-10       Impact factor: 3.780

Review 6.  What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?

Authors:  Benedikt Zott; Marc Aurel Busche; Reisa A Sperling; Arthur Konnerth
Journal:  Annu Rev Neurosci       Date:  2018-07-08       Impact factor: 12.449

Review 7.  The role of innate immunity in Alzheimer's disease.

Authors:  Hannah E Ennerfelt; John R Lukens
Journal:  Immunol Rev       Date:  2020-06-26       Impact factor: 12.988

Review 8.  Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets.

Authors:  Alexandra Grubman; Katja M Kanninen; Tarja Malm
Journal:  J Mol Neurosci       Date:  2016-09-22       Impact factor: 3.444

Review 9.  Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease.

Authors:  Nathaniel S Woodling; Katrin I Andreasson
Journal:  ACS Chem Neurosci       Date:  2016-04-04       Impact factor: 4.418

Review 10.  Trafficking in Alzheimer's Disease: Modulation of APP Transport and Processing by the Transmembrane Proteins LRP1, SorLA, SorCS1c, Sortilin, and Calsyntenin.

Authors:  Simone Eggert; Carolin Thomas; Stefan Kins; Guido Hermey
Journal:  Mol Neurobiol       Date:  2017-10-27       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.